Chimerism, graft survival, and withdrawal of immunosuppressive drugs in HLA matched and mismatched patients after living donor kidney and hematopoietic cell transplantation

American Journal of Transplantation

Volumn 15, Issue 3, 2015, Pages 695-704

  Scandling, J D ^a   Busque, S ^a   Shizuru, J A ^a   Lowsky, R ^a   Hoppe, R ^a   Dejbakhsh Jones, S ^a   Jensen, K ^a   Shori, A ^a   Strober, J A ^a   Lavori, P ^a   Turnbull, B B ^a   Engleman, E G ^a   Strober, Samuel ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

bone marrow hematopoietic stem cell transplantation; clinical research practice; kidney transplantation nephrology; tolerance: chimerism; tolerance: clinical; translational research science

Indexed keywords

CD34 ANTIGEN; CREATININE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ACUTE PYELONEPHRITIS; ADULT; ARTICLE; CD3+ T LYMPHOCYTE; CHIMERA; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DRUG TOLERANCE; DRUG WITHDRAWAL; END STAGE RENAL DISEASE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES ZOSTER; HLA SYSTEM; HOSPITAL READMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DONOR; KIDNEY GRAFT; LIVING DONOR; LYMPH NODE IRRADIATION; MALE; MIXED LYMPHOCYTE REACTION; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RECURRENT DISEASE; THROMBOTIC THROMBOCYTOPENIC PURPURA; URETER STRICTURE; VIREMIA; COHORT ANALYSIS; KIDNEY TRANSPLANTATION; MIDDLE AGED; YOUNG ADULT;

ADULT; CHIMERISM; COHORT STUDIES; FEMALE; GRAFT SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVING DONORS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84923230601     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13091     Document Type: Article

References (21)

1. Spitzer TR, Sykes M, Tolkoff-Rubin N, et al. Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease. Transplantation 2011; 91: 672-676.
2. Kawai T, Sachs DH, Sykes MD, Cosimi MD., HLA-mismatched renal transplantation without maintenance immunosuppression. NEJM 2008; 358: 353-361.
3. Kawai T, Sachs DH, Sykes M., Cosimi AB., HLA-mismatched renal transplantation without maintenance imunosuppression. NEJM 2013; 368: 1850-1852.
4. Millan MT, Shizuru JA, Hoffman P, et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation 2002; 73: 1386-1391.
5. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantataion. N Engl J Med 2008; 358: 362-368.
6. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and withdrawal of immunosuppressive drugs in patients given kidney and hematopoietic cell transplants. AJT 2012; 12: 1133-1145.
7. Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S., Induced immune tolerance for kidney transplantation. New Engl. J. Med 2011; 365: 1359-1360.
8. Leventhal J, Abecassis M, Miller J, et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med 2012; 4: 124ra28.
9. Leventhal J, Abecassis M, Miller J, et al. Tolerance induction in HLA disparate living donor kidney transplantation by donor stem cell infusion: Durable chimerism predicts outcome. Transplantation 2013; 95: 169-176.
10. Leventhal JR, Mathew JM, Salomon DR, et al. Genomic biomarkers correlate with HLA-identical renal transplant tolerance. J Am Soc Nephrol 2013; 24: 1376-1385.
11. Lowsky R, Takahashi T, Liu UP, et al. Protective conditioning for acute graft-versus-host disease. N Engl J Med 2005; 353: 1321-1331.
12. Tiong HY, Goldfarb DA, Kattan MW, et al. Nomograms for predicting graft function and survival in living donor kidney transplantation based on the UNOS registry. J Urol 2009; 181: 1248-1255.
13. + T-cell dose. Blood 2005; 105: 2300-2306.
14. Urbano-Ispizua A, Rozman C, Pimentel P, et al. The number of donor CD3+ cells is the most important factor for graft failure after allogeneic transplantation of CD34+ selected cells from peripheral blood from HLA-identical siblings. Blood 2001; 97: 383-387.
15. Farris AB, Taheri D, Kawai T, et al. Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone marrow allografts. Am J Transplant 2011; 11: 1464-1477.
16. Manilay JO, Pearson DA, Sergio JJ, Swenson KG, Sykes M., Intrathymic deletion of alloreactive T cells in mixed bone marrow chimeras prepared with a nonmyeloablative conditioning regimen. Transplantation 1998; 66: 96-102.
17. Wood KJ, Sakaguchi S, Regulatory, T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199-210.
18. Waldmann H, Hilbrands R, Howie D, Cobbold S., Harnessing FOXP3+ regulatory T cells for transplantation tolerance. J Clin Invest 2014; 124: 1439-1445.
19. Kendal AR, Chen Y, Regateiro FS, et al. Sustained suppression by Foxp3+ regulatory T cells is vital for infectious transplantation tolerance. J Exp Med 2011; 208: 2043-2053.
20. Bolanos-Meade J, Fuchs EJ, Luznik L, et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012; 120: 4285-4291.
21. Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood 2011; 118: 282-288.